# Harvard Apparatus Regenerative Technology, Inc. (HRGN) · Edgar & Edgarette company card

> Harvard Apparatus Regenerative Technology (HRGN) grew revenue 63.7% in FY2025 to $1 million, operating margin -982% against a 1.2% median for surgical & medical instruments & apparatus, equity 39.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1563665 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/HRGN) · [JSON](https://www.pops4.com/boards/company/HRGN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $704,000 |
| Revenue growth, 1 year | 63.7% |
| Revenue growth per year | — |
| Operating margin | -982.2% (prior year -1796.7%) |
| Net margin | -975.7% |
| Operating cash flow | −$4M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $1M |
| Long-term debt | — |
| Total assets | $3M |
| Total equity | $1M |
| Equity ÷ assets | 39.5% |
| Return on equity | -649.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -145.71 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$3.8M in FY2025); operating loss: a margin of -982.2% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $704K (FY2025). Experience: revenue up 63.7% on the year; operating margin -982.2%, up from -1796.7%. Soundness: equity 39.5% of assets, return on equity -649.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $846K and $1.5M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -982.2% against a 1.2% median; growth 63.7% against 11.6%.

Range logged 2026-10-09, receipt 587331c72e791acf, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-11-13 · [filing](https://www.sec.gov/Archives/edgar/data/1563665/000143774926036714/0001437749-26-036714-index.htm)
- 8-K · filed 2026-09-14 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1563665/000143774926030244/0001437749-26-030244-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1563665/000143774926027566/0001437749-26-027566-index.htm)
- 8-K · filed 2026-08-03 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1563665/000143774926025423/0001437749-26-025423-index.htm)
- 8-K · filed 2026-06-24 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1563665/000143774926021480/0001437749-26-021480-index.htm)
- 10-Q · filed 2026-05-13 · [filing](https://www.sec.gov/Archives/edgar/data/1563665/000143774926016761/0001437749-26-016761-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001563665.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1563665

## Cite

POPS4, Edgar & Edgarette: Harvard Apparatus Regenerative Technology, Inc. (HRGN) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/HRGN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

